Sign in

NCT06152302Recruiting

Test of Aquatic Mobility of SMA Infants

Analysis of Mobility in the Bath for Infants Affected With Spinal Muscular Atrophy

Source: ClinicalTrials.gov · Last updated 21 Nov 2025

Brief summary (registry, in English)

Spinal muscular atrophy (SMA) is a genetic neurodegenerative disease impacting spinal cord motor neurons, leading to motor and respiratory issues and, ultimately, death. With emerging therapies, a need arises to enhance motor function assessment in severely hypotonic infants (SMA type 1) as traditional scales on examination tables lack completeness due to gravity's influence. The study team has developed a "bath test" to observe infants' motor skills in water, eliminating gravity's effects. This test aims to detect subtle movements using inertial sensors, potentially revealing more active motor neurons in aquatic conditions. It aids in identifying infants with motor improvement potential, even if they show limited mobility outside water, and tracks disease progression and therapy responses. Presently, pediatric neurologists in France use parent-provided bathing videos for evaluations, but these lack standardization and precision. The study aims to establish a standardized evaluation protocol with quantifiable data. The study's key objective is to evaluate severely hypotonic SMA infants using inertial sensors, including accelerometers, gyrometers, and magnetometers. The study will conduct "dry" and "water" assessments using a specially designed bathtub. This method's goal is to quantify water-based movements accurately. Simultaneously, the study seeks to establish semi-quantitative evaluation criteria to create a clinical assessment scale for infant motor function in bathtubs. This scale will aid doctors in therapeutic decisions. The study will not influence the treatment or therapeutic decisions made for the children being tested. Collected data from "dry" and "water" conditions will be statistically analyzed and compared to reference motor assessment scales (e.g., CHOP INTEND and HINE) and electromyography (CMAP-EMG) results, commonly used in diagnosis and monitoring. Blurred video recordings will assist in protocol monitoring and sensor data analysis.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
15 (estimated)
First submitted
30 Oct 2023
Start date
26 Jun 2025
Primary completion date
30 Jun 2026
Lead sponsor
Assistance Publique - Hôpitaux de Paris
NCT number
NCT06152302

What you commit to

  • Study type: Interventional
  • Planned participants: 15
  • From 26 Jun 2025 to the primary completion date, 30 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients presenting with lesions in the spinal cord or conditions affecting the cardiorespiratory system.

Other

  • Patients covered under the French Aid in Health for Foreign People program (AME).

Who the study is looking for

  • Infants with muscle weakness (commonly referred to as floppy babies):
    • Confirmed diagnosis of SMA through gene mutation or deletion (SMN1 gene).
    • Receiving standard care.
    • Age less than 12 years and a height of less than 90 cm at the time of inclusion.
  • Patients enrolled in a social security scheme.
  • Informed consent signed by both parents of the child and the investigator.

Age in the registry: - to 12 months · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Infantile neuromuscular unity - Department of paediatric neurological care and intentive care unity, Raymond Poincaré Hospital - APHP
Coordinator of this site? Confirm its status
GarchesFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.